1. Home
  2. XENE vs CRSP Comparison

XENE vs CRSP Comparison

Compare XENE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenon Pharmaceuticals Inc.

XENE

Xenon Pharmaceuticals Inc.

HOLD

Current Price

$59.75

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$55.79

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XENE
CRSP
Founded
1996
2013
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.8B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
XENE
CRSP
Price
$59.75
$55.79
Analyst Decision
Strong Buy
Buy
Analyst Count
11
17
Target Price
$68.55
$70.29
AVG Volume (30 Days)
621.9K
1.3M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$311,000.00
$289,590,000.00
Revenue This Year
N/A
$807.72
Revenue Next Year
$2,496.48
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$35.60
$44.12
52 Week High
$72.66
$78.48

Technical Indicators

Market Signals
Indicator
XENE
CRSP
Relative Strength Index (RSI) 43.69 52.29
Support Level $52.40 $50.45
Resistance Level $62.91 $59.94
Average True Range (ATR) 2.20 2.72
MACD -0.22 -0.25
Stochastic Oscillator 17.95 41.78

Price Performance

Historical Comparison
XENE
CRSP

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: